2-es típusú cukorbetegség: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• GLP-1 66
• SGLT2 41
• PPAR 0
• AMPK 2
• DPP-4 7
• PI3K 0
• AKT 0
• GIP 4
• mTOR 0
• NRF2 0
• NLRP3 3
• SIRT1 1
• STAT3 0
• TP53 1
• TNF 0
• MAPK 0
• PCSK9 1
• VEGF 2
• JNK 0
• TLR4 0
• FTO 0
• IL-6 2
• ERK 0
• HIF-1 0
• JAK 0
• HMGB1 0
• APOE 0
• BDNF 0
• IL-1 1
• STING 0
• CTNNB1 0
• GPX4 0
• PTEN 0
• STK11 0
• IL-17 1
• MMP-9 1
• BCL-2 0
• COX-2 0
• MEK 0
• PINK1 0
• CD40 0
• EGFR 0
• PD-1 0
• RANKL 0
• YAP 0
• ATM 0
• FGFR 0
• MET 1
• PD-L1 0
• SNCA 0
• CCR5 0
• CDKN2A 0
• CXCR4 0
• IGF1R 0
• MAPT 0
• METTL3 0
• PNPLA3 0
• ABL1 0
• BACE1 0
• CD38 0

3+ intézményből 3, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spanyolország· EU contribution 209 915 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unmasking the Perivascular Adipose Tissue's Role in Diabetic Vascular Disease From Molecular Clues to Clinical Impact (IMAPERFAT)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 236 340 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Bridging Chronobiology and Physiology through Expert Training (ChronoBridge)

  Ecole Polytechnique Federale de Lausanne· Lausanne, Svájc· EU contribution 3 885 022 EUR· until 2030. dec.· 9 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  AI-Powered and Robot-Assisted Opto-Acoustic Evaluation of Systemic Microangiopathy for Ulcer Healing Outcomes in Type 2 Diabetes (ARETEOS)

  Universitatsklinikum Erlangen· Erlangen, Németország· EU contribution 1 499 068 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  First-in-man beta-cell regeneration for causal type 2 diabetes therapy (BetaProtect)

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Németország· EU contribution 150 000 EUR· until 2028. ápr.

5 of 59 running projects, newest first. Listed amounts together: 152,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Frissítve: 2026. okt. 16.

  “poor accrual and funding issues”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Effects of DPP-4 Inhibition on Triglycerides

  NCT01527747· Oregon Health and Science University· Frissítve: 2023. ápr. 7.

  “Funding”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Forrás

• LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

  NCT05313529· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Forrás

• A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy

  NCT03499704· Celltrion Pharm, Inc.· Forrás

• Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

  NCT04323189· University of Pennsylvania· Forrás

• DPP4-Inhibitors and Bone Metabolism in Diabetes

  NCT06770894· Azienda Policlinico Umberto I· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 26
• Organoids 3
• Mendelian Randomization Analysis 228
• CRISPR-Cas Systems 5
• Gene Expression Profiling 113
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 8
• Exome Sequencing 12
• Proteomics 148
• Metabolomics 202
• Mass Spectrometry 42
• Flow Cytometry 19
• Immunohistochemistry 50
• Xenograft Model Antitumor Assays 34
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 187
• Machine Learning 196
• Deep Learning 32
• Cohort Studies 1112
• Genome-Wide Association Study 315

• Causal relationship between educational attainment and complications of Type 2 diabetes: Mendelian randomization study.

  Medicine (Baltimore), 2026. nov.

• Association Between Genetically Predicted 25-Hydroxyvitamin D and Type 2 Diabetes Risk in South Asians: An Exploratory Two-Sample Mendelian Randomization Study.

  Endocrinol Diabetes Metab, 2026. nov.

• Hypoglycemic Agent Targets and Susceptibility to Lower Respiratory Infection: A Pharmacogenomic Mendelian Randomization Study.

  Genes (Basel), 2026. okt.

• Genetic risk factors and causal associations with sudden cardiac arrest: A Mendelian randomization study.

  Medicine (Baltimore), 2026. okt.

• Body mass index and type 2 diabetes liability in osteomyelitis and cellulitis: A cross-biobank Mendelian randomization study.

  Medicine (Baltimore), 2026. okt.

• The causal relationship between diabetes mellitus and hashimoto thyroiditis: A two-sample mendelian randomization analysis.

  Medicine (Baltimore), 2026. okt.

• Metabolomics-Defined Subtypes of Prediabetes and Risk of Cardiovascular-Kidney-Metabolic Outcomes.

  Diabetes, 2026. okt.

• Genetically Proxied GIP-GIPR Pathway Perturbation and Fracture Risk.

  Diabetes Obes Metab, 2026. szept.

• Genetic factor analysis for characterizing phenome-wide patterns of genetic pleiotropy.

  Nat Genet, 2026. szept.

• Cataract GWAS meta-analysis and multi-omics Mendelian randomisation inform disease mechanisms and candidate target prioritisation.

  EBioMedicine, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.